Search

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, in San Diego, California.

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the Northeast, the number two cancer hospital in the nation, and the number one hospital for urology care by U.S. News & World Report in its annual Best Hospitals list. MSK has held its position as a top-two cancer hospital in the U.S. and the best cancer center in the Northeast since these rankings were established 35 years ago.

MSK researchers have led much of the research looking at how people with blood cancers respond to COVID-19 infections and vaccines.

New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.